Tigecycline (INN) is an glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was given a U.S. Food and Drug Administration (FDA) fast-track approval and was approved on June 17, 2005. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. Pharmacology This antibiotic is the first clinically-available drug in a new class of antibiotics called the glycylcyclines. It is structurally similar to… (More on Tigecycline)